Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.30 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30473641 | 0.83 | DGAT1 (0.40) | CYP2D6DGAT1HDAC3HDAC1HDAC2 | |
| SCHEMBL189917 | 0.83 | GGT1 (0.41) | CYP2D6DGAT1 | |
| SCHEMBL6534711 | 0.80 | CYP2D6 (0.33) | STING1MAOAMAOBCYP2D6DGAT1 | |
| SCHEMBL7826803 | 0.79 | DGAT1 (0.34) | STING1MAOAMAOBCYP2D6DGAT1 | |
| SCHEMBL31238586 | 0.79 | HDAC3 (0.37) | STING1MAOAMAOBCYP2D6DGAT1 | |
| SCHEMBL8395320 | 0.79 | DGAT1 (0.47) | STING1MAOAMAOBCYP2D6DGAT1 | |
| SCHEMBL28832570 | 0.77 | DGAT1 (0.33) | STING1MAOAMAOBCYP2D6DGAT1 | |
| SCHEMBL27443265 | 0.76 | CYP2D6 (0.33) | STING1CYP2D6DGAT1HDAC3HDAC1 | |
| SCHEMBL1540854 | 0.74 | TDP1 (0.32) | CYP2D6DGAT1HDAC3HDAC1HDAC2 | |
| SCHEMBL6534835 | 0.74 | KDM4E (0.35) | CYP2D6DGAT1HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1028942-B1 | DIPEPTIDE NITRILES | NOVARTIS AG (CH) | 2010-09-01 | — | — | EP | disclosed |
| US-20080027060-A1 | DIPEPTIDE NITRILES | ALTMANN EVA | 2008-01-31 | — | — | US | disclosed |
| US-20060235220-A1 | Dipeptide nitriles | MISSBACH MARTIN | 2006-10-19 | — | — | US | disclosed |
| US-20040110806-A1 | Dipeptide derivatives | ALTMANN EVA (CH) | 2004-06-10 | — | — | US | disclosed |
| US-20040029814-A1 | Dipeptide nitriles | ALTMANN EVA (CH) | 2004-02-12 | — | — | US | disclosed |
| US-6353017-B1 | INHIBITORS OF CATHESPINS USING DIPEPTIDE NITRILES AS ANTIINFLAMMATORY AGENTS AND ANTIARTHRITIC AGENTS | NOVARTIS AG (CH) | 2002-03-05 | — | — | US | disclosed |
| EP-1028942-A2 | DIPEPTIDE NITRILES | Novartis AG (CH) | 2000-08-23 | — | — | EP | disclosed |
| WO-1999024460-A2 | DIPEPTIDE NITRILES | NOVARTIS AG (CH) | 1999-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110806-A1 | Dipeptide derivatives | CTSL, CTSZ, CTSS | STING1 1108/4885MAOA 4103/4885MAOB 2700/4885 |
| US-20040029814-A1 | Dipeptide nitriles | NOS1, CTSL, CTSS | STING1 554/4885MAOA 3045/4885MAOB 1607/4885 |
| US-20060235220-A1 | Dipeptide nitriles | CTSL, CTSS, CTSB | STING1 996/4885MAOA 3705/4885MAOB 2178/4885 |
| US-20080027060-A1 | DIPEPTIDE NITRILES | CTSL, CTSS, CTSB | STING1 996/4885MAOA 3705/4885MAOB 2178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.